Risks and benefits of biologic therapy for inflammatory bowel diseases.

Top-down therapy for IBD: rationale and requisite evidence. Nat Rev Gastroenterol Hepatol (2010) 1.09

Optimizing the safety of biologic therapy for IBD. Nat Rev Gastroenterol Hepatol (2010) 0.85

Huangqin-Tang Ameliorates TNBS-Induced Colitis by Regulating Effector and Regulatory CD4(+) T Cells. Biomed Res Int (2015) 0.80

Safety profile of biologic therapy in Polish paediatric patients with Crohn's disease. Prz Gastroenterol (2015) 0.75

Bias in analytic research. J Chronic Dis (1979) 16.40

Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA (2006) 15.65

Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N Engl J Med (2006) 15.04

Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med (2005) 14.50

Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet (2002) 14.14

Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum (2003) 8.50

Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med (2003) 8.49

Anti-interleukin-12 antibody for active Crohn's disease. N Engl J Med (2004) 7.93

Progressive multifocal leukoencephalopathy in a patient treated with natalizumab. N Engl J Med (2005) 7.04

Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med (2004) 6.77

Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. Gastroenterology (2006) 6.36

Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease. N Engl J Med (2005) 6.33

Natalizumab induction and maintenance therapy for Crohn's disease. N Engl J Med (2005) 5.36

Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy. N Engl J Med (2006) 5.20

Inflammatory bowel disease is not associated with an increased risk of lymphoma. Gastroenterology (2001) 4.28

Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease. Gastroenterology (2004) 4.26

Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial. Circulation (2003) 4.19

Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry. Clin Gastroenterol Hepatol (2006) 4.18

Treatment of ulcerative colitis with a humanized antibody to the alpha4beta7 integrin. N Engl J Med (2005) 3.56

The safety profile of infliximab in patients with Crohn's disease: the Mayo clinic experience in 500 patients. Gastroenterology (2004) 3.50

Risks and benefits of infliximab for the treatment of Crohn's disease. Clin Gastroenterol Hepatol (2006) 2.88

Outcome of pregnancy in women receiving infliximab for the treatment of Crohn's disease and rheumatoid arthritis. Am J Gastroenterol (2004) 2.45

Sargramostim for active Crohn's disease. N Engl J Med (2005) 2.24

Chronic hepatitis B reactivation following infliximab therapy in Crohn's disease patients: need for primary prophylaxis. Gut (2004) 2.03

Optimizing anti-TNF treatment in inflammatory bowel disease. Gastroenterology (2004) 1.97

Intentional infliximab use during pregnancy for induction or maintenance of remission in Crohn's disease. Aliment Pharmacol Ther (2005) 1.96

Anti-tumor necrosis factor-alpha-induced psoriasis. J Rheumatol (2006) 1.64

Utility of the antigen-specific interferon-gamma assay for the management of tuberculosis. Curr Opin Pulm Med (2005) 1.60

Autoimmunity associated with anti-tumor necrosis factor alpha treatment in Crohn's disease: a prospective cohort study. Gastroenterology (2003) 1.52

Fontolizumab, a humanised anti-interferon gamma antibody, demonstrates safety and clinical activity in patients with moderate to severe Crohn's disease. Gut (2006) 1.52

Complications of biological therapy for inflammatory bowel diseases. Curr Opin Gastroenterol (2006) 1.12

Infliximab and reactivation of cerebral toxoplasmosis. N Engl J Med (2005) 1.10

A case of hepatosplenic gamma-delta T-cell lymphoma with a transient response to fludarabine and alemtuzumab. Eur J Haematol (2006) 1.02

Adverse skin reactions to anti-TNF-alpha monoclonal antibody therapy. Dermatology (2003) 1.01

Biologics in inflammatory bowel disease: how much progress have we made? Gut (2004) 0.99

Infliximab for rheumatoid arthritis in a patient with tuberculosis. N Engl J Med (2006) 0.99

Hepatosplenic T-gammadelta lymphoma in a patient with Crohn's disease treated with azathioprine. Leuk Lymphoma (2003) 0.97

Infliximab for the treatment of psoriasis. Expert Opin Biol Ther (2006) 0.93